Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 5, 2007, Pages 866-873

  Chan, Raphael C Y ^a   Hui, Mamie ^a   Chan, Edward W C ^a   Au, T K ^a   Chin, Miu L ^a   Yip, Chun K ^a   AuYeang, Carrie K W ^a   Yeung, Christina Y L ^a   Kam, Kai M ^b   Yip, Peter C W ^b   Cheng, Augustine F B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

MDR TB; MPAC; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ETHAMBUTOL; GENE PRODUCT; ISONIAZID; KATG PROTEIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CLINICAL LABORATORY; CONTROLLED STUDY; DNA SEQUENCE; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC CORRELATION; HONG KONG; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ANTITUBERCULAR AGENTS; GENES, BACTERIAL; HONG KONG; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUBERCULOSIS;

EID: 34447532427     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm054     Document Type: Article

References (34)

1. Frieden TR, Sterling TR, Munsiff SS et al. Tuberculosis. Lancet 2003; 362: 887-99.
2. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72: 1.
3. Annual Report 2002, Tuberculosis and Chest Service of the Department of Health, The Government of the Hong Kong SAR, China. http://www.info.gov.hk/tb_chest/doc/Annurept_2002.pdf (10 January 2007, date last accessed).
4. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231-49.
5. Pozniak A. Multidrug-resistant tuberculosis and HIV infection. Ann NY Acad Sci 2001; 953: 192-8.
6. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002; 325: 1282-6.
7. Crofton J, Chaulet P, Maher D. Guidelines for the Management of Drug-resistant Tuberculosis, 1st edition. Geneva, Switzerland: World Health Organization, 1997.
8. Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004; 54: 593-602.
9. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tubrculosis. In: Hatfull GF, Jacobs WR Jr ed. Molecular genetics of Mycobacteria. Washington, D.C.: ASM Press, 2000; 235-54.
10. Cheng AF, Yew WW, Chan EW et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
11. Canetti G, Wallace F, Khomenko A et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull WHO 1969; 41: 21-43.
12. Van Soolingen D, Hermans PWM, De Haas PEW et al. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: Evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 40: 2578-86.
13. Siddiqi N, Shamim M, Hussain S et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 2002; 46 443-50.
14. Taniguchi H, Aramaki HH, Nikaido Y et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett 1996; 144: 103-8.
15. Bottger EC, Springer B, Pletschette M et al. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 1998; 4: 1343-4.
16. Levin BR, Perrot V, Walker N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 2000; 154: 985-97.
17. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
18. Suresh N, Singh UB, Arora J et al. rpoB gene sequencing and spoligotyping of multidrug-resistant Mycobacterium tuberculosis isolates from India. Infect Genet Evol 2006; 6: 474-83.
19. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-12.
20. Hazbon MH, Bobadilla del Valle M, Guerrero M et al. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: A novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother 2005; 49: 3794-802. Erratum in: Antimicrob Agents Chemother 2005; 49: 4818.
21. Morlock GP, Metchock B, Sikes D et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-805.
22. Ahmad S, Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents 2005; 6: 205-12.
23. Huang H, Jin Q, Ma X et al. Characterization of rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolated in China. Tuberculosis (Edinb) 2002; 82: 79-83.
24. Yue J, Shi W, Xie J et al. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2003; 41: 2209-12.
25. Qian L, Abe C, Lin TP et al. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol 2002; 40: 1091-4.
26. Escalante P, Ramaswamy S, Sanabria H et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis 1998; 79: 111-8.
27. Yam WC, Tam CM, Leung CC et al. Direct detection of rifampin-resistant Mycobacterium tuberculosis in respiratory specimens by PCR-DNA sequencing. J Clin Microbiol 2004; 42: 4438-43.
28. Cardoso RF, Cooksey RC, Morlock GP et al. Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrob Agents Chemother 2004; 48: 3373-81.
29. Leung ET, Ho PL, Yuen KY et al. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: Identification of a novel mutation in inhA. Antimicrob Agents Chemother 2006; 50: 1075-8.
30. Mdluli K, Sherman DR, Hickey MJ et al. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 1996; 174: 1085-90.
31. O'Sullivan DM, McHugh TD, Gillespie SH. Analysis of rpoB and pncA mutations in the published literature: An insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J Antimicrob Chemother 2005; 55: 674-9.
32. Johnson R, Jordaan AM, Pretorius L et al. Ethambutol resistance testing by mutation detection. Int J Tuberc Lung Dis 2006; 10 68-73.
33. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997; 24 (Suppl. 1): S121-30.
34. Hillemann D, Weizenegger M, Kubica T et al. Use of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005, 43: 3699-703.